Monday, September 13, 2021

OCRA-Funded Study Identifies Antibiotic Found to Kill Tumor Cells Containing BRCA Mutations


This article was posted on the OCRA website on June 30, 2021.     

"A long-running study from Dana-Farber Cancer Institute, published in Nature Cancer and co-funded by OCRA, has discovered that the antibiotic novobiocin is capable of targeting and killing tumor cells in laboratory cell lines and tumor models with BRCA1 or BRCA2 genetic mutations–and is effective even in tumors that have become resistant to PARP inhibitors."


No comments:

Post a Comment